Market Scope

Trusted Partner of Industry and Medical Professionals for Market Data, Independent Perspective, & Objective Analysis

Latest Reports Latest News

Market Scope Methodology

A Multi-Step Approach for Accurate & Timely Data

Proprietary data

  • 20+ years of physician survey data
  • Exclusive manufacturer-reported metrics
  • Cultivated database of physicians, ASCs, and hospitals
  • Insight from our team of in-house industry experts

Public data

  • Attendance and participation at major, worldwide meetings
  • Public health systems and registries
  • Clinical study data
  • Analysis of company-published financial reports

Physician Surveys

For 20+ years, we have surveyed physicians to provide both physicians & industry professionals unbiased insight into the market.

Complete a Survey

On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.

Benchmark Your Performance

Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.

View Market Insights & Analytics

Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.

Learn More Register Today

Latest Market Reports

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.

Latest Industry News & Trends

orthopedicpress release
Market Scope Announces Launch of New Website and Entry into Orthopedics

Market Scope, an industry leader for ophthalmic market research, announced today the launch of its new website and the firm’s entry into orthopedics, its second medical vertical. The new Market-Sco...

Allergan Loses Appeal on Restasis Patents, Opening Door for Generics

The US Court of Appeals for the Federal Circuit in Washington on Nov. 13 affirmed a lower court decision invalidating the patents for Restasis. The appeals court made its ruling a week after it hea...

Ophthotech Drops Wet AMD Program for Zimura to Focus on Other Indications

Ophthotech has dropped its pursuit of a wet age-related macular degeneration (AMD) indication for Zimura in combination with Lucentis, the New York-based company announced Nov. 13. Zimura combinati...

Omeros Announces $210 Convertible Debt Offering

Omeros Corporation is looking to raise $210 million in a convertible debt offering, the Seattle-based company announced Nov. 13. The company has granted initial purchasers of the notes an option to...

4D Molecular Therapeutics Gains Orphan Drug Designation for Choroideremia Treatment

The US FDA has granted orphan drug designation to 4D Molecular Therapeutics’ treatment candidate for choroideremia, 4D-110, the Emeryville, California, company announced Nov. 16. 4D-110 is administ...

AsclepiX Raises $5 Million in Support of Candidate for DME, AMD

AsclepiX Therapeutics announced Nov. 13 that it has raised $5 million in convertible note funding. The Baltimore company said it will use the funds to develop AXT107, its treatment candidate for di...

RetiPharma Nets $1.48 Million to Develop Degenerative Eye Disorder Treatments

RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII) in the form of a convertible note to be paid in tranches totaling €1.3 million (about $1.48 million),...

Notal Vision Appoints Susan Orr as CEO

Notal Vision has appointed Susan Orr, OD, to become its next CEO, effective Jan. 1, 2019, the company announced Nov. 1. Orr will replace Quinton Oswald, who will retire at the end of 2018 but will ...

Join Market Scope Today

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Register A Clinical Account

A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.

US Surveys
May select more than one
Outside of US Surveys